Skip to main content
Premium Trial:

Request an Annual Quote

Resolve Biosciences, Zeiss Partner to Enhance Spatial Biology Imaging Tech

NEW YORK — Spatial biology startup Resolve Biosciences has partnered with optics firm Zeiss on the development of new microscopy and 3D imaging technologies, the German companies said on Tuesday.

Resolve, which was founded by former Qiagen executives and emerged from stealth mode in late 2020 following a $24 million Series A round, has developed a spatial biology analysis platform — dubbed Molecular Cartography — for viewing transcriptome activity at subcellular resolution. The platform includes Zeiss microscopy technology and is slated for commercial launch later this year.

Under the terms of their collaboration, Zeiss, headquartered in Jena, and Resolve, based in Monheim am Rhein, will develop new optical systems and computational approaches to enhance the Molecular Cartography workflow. Resolve said that it aims to eventually add DNA, protein, and metabolomic data layers to the technology.

Financial and other terms of the agreement were not disclosed.

The Scan

Removal Inquiry

The Wall Street Journal reports that US lawmakers are seeking additional information about the request to remove SARS-CoV-2 sequence data from a database run by the National Institutes of Health.

Likely to End in Spring

Free lateral flow testing for SARS-CoV-2 may end in the UK by next spring, the head of Innova Medical Group says, according to the Financial Times.

Searching for More Codes

NPR reports that the US Department of Justice has accused an insurance and a data mining company of fraud.

Genome Biology Papers on GWAS Fine-Mapping Method, COVID-19 Susceptibility, Rheumatoid Arthritis

In Genome Biology this week: integrative fine-mapping approach, analysis of locus linked to COVID-19 susceptibility and severity, and more.